Brad Navia

Company: Aprinoia Therapeutics Inc.

Job title: Chief Medical Officer

Seminars:

Panel Discussion: Defining Biomarker Context of Use in Early on to Ensure Valuable Insights from Clinical Implementation into Neurology Trials 3:45 pm

Critically evaluating correct and valuable applications of biomarkers for meaningful and actionable insights: target engagement, patient stratification, diagnosis, prognosis and predicting patient outcome • Addressing regulatory requirements and validation processes necessary for biomarkers in clinical trials and discuss strategies for robust biomarker validation to ensure reliability and reproducibility of results across different patient populations and…Read more

day: Conference Day One

Exploring the Utility of APN1607 as a First In Class Diagnostic Marker for Tauopathies for Earlier Identification of Patients 1:15 pm

Discussing and reviewing landscape of imaging markers for tau for neurodegenerative disorders Discussing the biological properties of APN1607 as a novel first in class PET tracer for 3R and 4R tauopathies Reviewing the clinical results on the utility of APN1607 across the spectrum of 3R and 4R tauopathies including AD, PSP, FTD and CTE Exploring…Read more

day: Conference Day One